PolyNovo Limited (ASX:PNV): NovoSorb Sales and Manufacturing Expansion Define FY26 Performance

Aditi Sarkar

30 October 2026 08:16 PM AEDT

PolyNovo Limited (ASX:PNV): NovoSorb Sales and Manufacturing Expansion Define FY26 Performance

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 revenue increased 16.1% YoY to $150.0m.
Commercial sales reached $138.4m, up 16.7% YoY.
Operating cash flow was $23.1m and free cash flow was $9.4m.
A new manufacturing facility was completed, with validation work ongoing.

PolyNovo Limited develops and commercialises medical devices based on its NovoSorb technology for burns and complex wound management. PolyNovo Limited (ASX:PNV) reported growth in its commercial product business in FY26 while pursuing manufacturing, clinical evidence and market-access initiatives.

Sales momentum across commercial markets

PolyNovo Limited (ASX:PNV) reported total FY26 revenue of $150.0m, up 16.1% YoY. Commercial product sales rose 16.7% YoY to $138.4m, or 21.3% on a constant-currency basis. Constant-currency growth excludes the impact of exchange-rate movements when comparing reporting periods, while the reported sales figure reflects the currency translation used in the accounts.

US NovoSorb sales reached $102.1m during FY26, representing growth of 15.6% YoY. Sales in the rest of the world were $36.3m, an increase of 20.0% YoY. The two geographic categories help explain the overall commercial revenue trend without implying that demand or distribution conditions were identical across every country.

PolyNovo Limited (ASX:PNV) has been extending the NovoSorb platform beyond its initial burns applications. Its FY26 announcement described progress with NovoSorb MTX commercialisation and ongoing work to expand supporting clinical evidence. Commercial rollout and clinical-evidence development are distinct processes, particularly where additional reimbursement or regulatory decisions are required.

Earnings, cash and production capacity

For FY26, PolyNovo Limited (ASX:PNV) reported EBITDA of $12.1m and net profit after tax of $7.3m. The net profit was 44.4% lower YoY, despite the increase in total revenue. The company reported an FY26 gross margin of 89.0%, compared with 95.6% in the comparative results, showing that a rise in sales does not necessarily produce the same movement across every earnings measure.

Operating cash flow was $23.1m, and reported free cash flow was $9.4m. Cash and cash equivalents stood at $35.4m at 30 June 2026. The difference between operational cash generation and free cash flow reflects, among other factors, investment in equipment and facilities needed for the business.

Construction of PolyNovo's expanded manufacturing facility was completed during FY26, with validation continuing before the planned operational transition in FY27. PolyNovo Limited (ASX:PNV) reported significantly higher manufacturing output in the second half, while noting that production systems and validation remain important to realising the benefit of expanded capacity.

Regulatory and commercial priorities

The company's FY26 annual reporting identified its US premarket approval submission for NovoSorb BTM in full-thickness burns among the priorities for the next reporting period. Regulatory submission activity is not the same as receiving an approval. PolyNovo Limited (ASX:PNV) also identified US outpatient reimbursement and global commercial expansion as areas of operational focus.

Additional work involves scaling the new facility and improving product development governance. The company's broader commercial approach combines direct markets with distribution arrangements, and the relative contribution of these channels may vary by geography and product application.

The FY26 figures illustrate revenue growth alongside a lower net profit and a continued commitment to manufacturing investment. The regulatory, clinical and manufacturing processes described by the company are ongoing activities rather than completed commercial outcomes.

In its annual reporting, the company described the new manufacturing facility as a capacity-building investment rather than a completed increase in commercial sales. Validation, process transfer and product-quality systems are separate tasks from construction, and the FY27 transition remained planned.

Key Insights

PolyNovo Limited (ASX:PNV) increased FY26 sales and generated positive operating cash flow, while net profit fell and manufacturing investment continued. The next operational stages involve facility validation, product development and market-access processes.

FAQs

Q: What was PolyNovo FY26 revenue?

A:$150.0m, up 16.1% YoY.

Q: How much did commercial product sales contribute?

A:$138.4m in FY26.

Q: What was the FY26 net profit?

A:$7.3m.

Q: How much operating cash flow was reported?

A:$23.1m.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.